Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
Authors:
Open Access
- 16 November 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 80 (1) , 31-39
Abstract
Amphetamines are the second most used illicit drugs worldwide and amphetamine-related hospitalizations are increasing substantially.1,2 There is an elevated risk of infections and mental disorders associated with methamphetamine or amphetamine use disorders (MAUD).1,3 People with MAUD are also at higher risk of mortality compared with the general population, mainly from directly drug-related deaths, but also due to suicide, homicide, cardiovascular disease, and injuries.4,5 Amphetamine use is associated with aggressive behavior and criminality, which also indirectly lead to morbidity and mortality.6 Mortality related to amphetamine or methamphetamine use is increasing7,8 and has doubled over the past decade, possibly indicating the next substance use crisis.9 According to the European Monitoring Centre for Drugs and Drug Addiction Sweden Country Drug Report 2019,10 amphetamines were the third most commonly used illicit drugs, and 1.2% of young adults aged 17 to 34 years were taking them. Concerning all the harm and costs that MAUD cause for the individual and society, effective treatments seem essential.11 However, there are currently no approved pharmacological interventions available for treating MAUD.6 Recent meta-analyses have investigated the effectiveness of antidepressants, antipsychotics, psychostimulants, anticonvulsants, and opioid agonists and antagonists3,6 and suggest that there are some promising candidates for the treatment of MAUD, yet convincing evidence is lacking.3 Treatment with the combination of extended-release injectable naltrexone and daily oral extended-release bupropion resulted in a low, but higher than placebo, response for methamphetamine-negative urine samples.12 In addition, the antidepressant mirtazapine has been reported to reduce methamphetamine use when combined with substance use counseling.13 The most consistent positive findings have been demonstrated with stimulant agonists (dexamphetamine14,15 and methylphenidate16-18), naltrexone,19,20 and topiramate,21 whereas antidepressants have shown less consistent results in reducing amphetamine use.3 A recent systematic review and meta-analysis22 evaluated agonist-based pharmacological interventions (similarly as used in opioid and tobacco use disorders) and found that prescription psychostimulants had a beneficial effect to promote abstinence in persons with stimulant use disorders. Dexamphetamine has similar neurochemical and behavioral effects to methamphetamine,23 and it has been used as an off-label treatment for MAUD. Lisdexamphetamine is a pharmacologically inactive prodrug of dexamphetamine. It presents a candidate pharmacotherapy for MAUD and seems relatively safe and well tolerated.24 However, studies tend to be limited by small sample sizes in defined populations and by low treatment retention or completion rates.3Keywords
This publication has 34 references indexed in Scilit:
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorderAddiction, 2014
- Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP studyAddiction, 2013
- Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trialAddiction, 2013
- Medication for Attention Deficit–Hyperactivity Disorder and CriminalityNew England Journal of Medicine, 2012
- Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled TrialAmerican Journal of Psychiatry, 2012
- Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trialAddiction, 2011
- A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine AddictionClinical Pharmacology & Therapeutics, 2010
- Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studiesAnnals of the New York Academy of Sciences, 2010
- Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceAddiction, 2009
- Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2008